Also; Timed release means lower peak concentrations and that probably means lower side effects. Even if side effects are minor, less is always better. What I read in the PR suggested that efficacy is not statistically significant, but it is improving. That would be similar to 2-73 before it matured. It seems possible that this class of drug in general needs a long time to work. If so, that might explain why it had been overlooked in the past. There are also minor differences between drugs that can make major differences in efficacy. I have seen it before. I have not followed 3-71 closely enough to say, but 2-73 is obviously very effective for Alz, in the longer run, for about half of the patients. That group of patients was not specified in advance... but hopefully the system is sophisticated enough to distinguish between rational precision medicine and random alignment. And... it's not like there was no signal in the other groups, it's just so dramatic in that group 3.
Market Data 
Markets 
AI
